Fluorescence in situ hybridization (FISH) is the most widely used ISH technique in clinical diagnostics. By tagging DNA probes with fluorescent dyes, FISH reveals gene amplifications, translocations, and deletions — the molecular signals that guide cancer diagnosis and targeted therapy. As precision oncology expands, FISH remains the dominant technology in the in situ hybridization market.

FISH is used to assess HER2 amplification in breast and gastric cancer, ALK and ROS1 rearrangements in lung cancer, and other biomarkers that determine eligibility for targeted drugs. According to in situ hybridization market analysis, FISH holds the largest technology share, driven by rising cancer incidence and expanding companion diagnostic requirements. Growth is supported by advances in probe design and automated imaging.

Innovation includes multiplex FISH, automated staining platforms, and quantitative analysis through digital pathology.

Challenges include cost, technical expertise, and tissue availability.

Yet the clinical need is clear, and the market is expected to grow as precision oncology expands.

People Also Ask

Q: What is FISH testing used for?
A: It detects gene amplifications, translocations, and deletions to guide cancer diagnosis and targeted therapy selection.

Q: Why is FISH important in cancer care?
A: It identifies biomarkers such as HER2 and ALK that determine eligibility for targeted therapies.

Tags: #FISH #PrecisionOncology #CompanionDiagnostics #HER2 #CancerDiagnostics #MarketDrivers